X4P-001 in cancer

X4P-001 is our lead CXCR4 inhibitor that is being investigated in Phase 1/2 trials in refractory clear cell renal cell carcinoma (ccRCC), melanoma, and other solid tumors. These cancers are aggressive and tend to break through treatment.

In multiple pre-clinical models of cancer, X4P-001 significantly reduced tumor growth and increased overall survival, both as a single agent and when used in combination with approved anti-cancer agents including tyrosine kinase inhibitors and various chemotherapies.

X4P-001 was previously tested in over 70 subjects in four prior clinical trials in healthy volunteers and HIV-infected patients and was shown to be well tolerated. Dose-dependent increases of immune cells in the blood was observed in all trials.